Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ZC3H18

Gene summary for ZC3H18

Gene summary.

Gene information	Species	Human
	Gene symbol	ZC3H18
	Gene ID	124245
	Gene name	zinc finger CCCH-type containing 18
	Gene Alias	NHN1
	Cytomap	16q24.2
	Gene Type	protein-coding
	GO ID	GO:0006139
	UniProtAcc	B4DTK7

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
124245	ZC3H18	LZE4T	Human	Esophagus	ESCC	2.67e-06	2.97e-01	0.0811
124245	ZC3H18	LZE7T	Human	Esophagus	ESCC	1.49e-06	3.78e-01	0.0667
124245	ZC3H18	LZE8T	Human	Esophagus	ESCC	7.56e-04	1.28e-01	0.067
124245	ZC3H18	LZE22T	Human	Esophagus	ESCC	2.08e-05	3.31e-01	0.068
124245	ZC3H18	LZE24T	Human	Esophagus	ESCC	2.90e-15	2.52e-01	0.0596
124245	ZC3H18	LZE21T	Human	Esophagus	ESCC	3.19e-03	1.93e-01	0.0655
124245	ZC3H18	P1T-E	Human	Esophagus	ESCC	1.83e-10	6.13e-01	0.0875
124245	ZC3H18	P2T-E	Human	Esophagus	ESCC	4.07e-22	4.64e-01	0.1177
124245	ZC3H18	P4T-E	Human	Esophagus	ESCC	6.44e-10	2.56e-01	0.1323
124245	ZC3H18	P5T-E	Human	Esophagus	ESCC	2.49e-12	2.19e-01	0.1327
124245	ZC3H18	P8T-E	Human	Esophagus	ESCC	3.10e-17	3.68e-01	0.0889
124245	ZC3H18	P9T-E	Human	Esophagus	ESCC	2.35e-06	1.57e-01	0.1131
124245	ZC3H18	P10T-E	Human	Esophagus	ESCC	1.46e-20	3.85e-01	0.116
124245	ZC3H18	P11T-E	Human	Esophagus	ESCC	7.78e-09	3.31e-01	0.1426
124245	ZC3H18	P12T-E	Human	Esophagus	ESCC	2.45e-20	4.59e-01	0.1122
124245	ZC3H18	P15T-E	Human	Esophagus	ESCC	2.36e-19	4.20e-01	0.1149
124245	ZC3H18	P16T-E	Human	Esophagus	ESCC	1.20e-13	2.39e-01	0.1153
124245	ZC3H18	P17T-E	Human	Esophagus	ESCC	2.20e-04	2.60e-01	0.1278
124245	ZC3H18	P19T-E	Human	Esophagus	ESCC	1.57e-02	2.31e-01	0.1662
124245	ZC3H18	P20T-E	Human	Esophagus	ESCC	2.16e-12	3.23e-01	0.1124

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0009896111	Esophagus	ESCC	positive regulation of catabolic process	332/8552	492/18723	4.36e-23	9.22e-21	332
GO:0031331111	Esophagus	ESCC	positive regulation of cellular catabolic process	292/8552	427/18723	8.67e-22	1.53e-19	292
GO:0006401110	Esophagus	ESCC	RNA catabolic process	204/8552	278/18723	3.39e-21	5.66e-19	204
GO:0034655110	Esophagus	ESCC	nucleobase-containing compound catabolic process	272/8552	407/18723	2.92e-18	2.90e-16	272
GO:004670018	Esophagus	ESCC	heterocycle catabolic process	286/8552	445/18723	1.12e-15	7.47e-14	286
GO:004427019	Esophagus	ESCC	cellular nitrogen compound catabolic process	288/8552	451/18723	3.03e-15	1.79e-13	288
GO:001943918	Esophagus	ESCC	aromatic compound catabolic process	295/8552	467/18723	1.09e-14	5.98e-13	295
GO:190136118	Esophagus	ESCC	organic cyclic compound catabolic process	307/8552	495/18723	9.99e-14	4.80e-12	307
GO:004348719	Esophagus	ESCC	regulation of RNA stability	117/8552	170/18723	7.91e-10	1.94e-08	117
GO:005077916	Esophagus	ESCC	RNA destabilization	63/8552	88/18723	7.23e-07	9.40e-06	63
GO:000989622	Liver	HCC	positive regulation of catabolic process	335/7958	492/18723	3.83e-31	1.87e-28	335
GO:003133122	Liver	HCC	positive regulation of cellular catabolic process	295/7958	427/18723	3.20e-29	1.45e-26	295
GO:004427021	Liver	HCC	cellular nitrogen compound catabolic process	303/7958	451/18723	9.76e-27	3.64e-24	303
GO:004670021	Liver	HCC	heterocycle catabolic process	299/7958	445/18723	2.07e-26	7.29e-24	299
GO:190136121	Liver	HCC	organic cyclic compound catabolic process	325/7958	495/18723	6.52e-26	2.18e-23	325
GO:001943921	Liver	HCC	aromatic compound catabolic process	309/7958	467/18723	1.56e-25	4.94e-23	309
GO:000640121	Liver	HCC	RNA catabolic process	201/7958	278/18723	3.88e-24	1.02e-21	201
GO:003465521	Liver	HCC	nucleobase-containing compound catabolic process	273/7958	407/18723	4.84e-24	1.23e-21	273
GO:004348721	Liver	HCC	regulation of RNA stability	119/7958	170/18723	3.20e-13	1.71e-11	119
GO:005077921	Liver	HCC	RNA destabilization	63/7958	88/18723	2.99e-08	6.77e-07	63

Page: 1 2 3

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ZC3H18

SNV

Missense_Mutation

novel

c.1645N>T

p.Pro549Ser

p.P549S

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.998)

TCGA-A2-A3XW-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamyicin

ZC3H18

SNV

Missense_Mutation

novel

c.2774N>G

p.Lys925Arg

p.K925R

protein_coding

deleterious_low_confidence(0.03)

probably_damaging(0.991)

TCGA-BH-A0B7-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

ZC3H18

SNV

Missense_Mutation

rs749335369

c.2657N>T

p.Ser886Leu

p.S886L

protein_coding

deleterious_low_confidence(0.01)

possibly_damaging(0.725)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

ZC3H18

insertion

Frame_Shift_Ins

novel

c.1480_1481insTTCATGTCTCTCAGGCATCTCCCCATTCACATGCTTCATGTCAG

p.Arg494LeufsTer55

p.R494Lfs*55

protein_coding

TCGA-AO-A0J5-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Other, specify in notesBisphosphonate

zoledronic

ZC3H18

insertion

In_Frame_Ins

novel

c.2306_2307insAGCAGCATATGGGCAGGGCAGACTCAGGTGCCAGTCCTGTGT

p.Arg769_Ser770insAlaAlaTyrGlyGlnGlyArgLeuArgCysGlnSerCysVal

p.R769_S770insAAYGQGRLRCQSCV

protein_coding

TCGA-BH-A0H7-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

ZC3H18

SNV

Missense_Mutation

novel

c.1696C>T

p.Arg566Trp

p.R566W

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.984)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

ZC3H18

SNV

Missense_Mutation

novel

c.2908C>T

p.Arg970Trp

p.R970W

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.997)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

ZC3H18

SNV

Missense_Mutation

rs267604676

c.1133G>A

p.Arg378Gln

p.R378Q

protein_coding

tolerated_low_confidence(0.05)

possibly_damaging(0.67)

TCGA-FU-A3TQ-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unknown

ZC3H18

SNV

Missense_Mutation

c.2752N>T

p.Pro918Ser

p.P918S

protein_coding

deleterious_low_confidence(0.05)

probably_damaging(0.998)

TCGA-JX-A3Q0-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unknown

ZC3H18

SNV

Missense_Mutation

rs201777324

c.1550N>A

p.Arg517His

p.R517H

protein_coding

deleterious_low_confidence(0.01)

probably_damaging(0.966)

TCGA-LP-A7HU-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1